- PharmAust (PAA) announces that all 12 patients in cohort three have received an initial escalated dose in its phase one/two trial of MPL in MND and ALS
- The trials are designed to test the tolerability, safety, pharmacokinetics and preliminary efficacy of the drug in people living with MND
- To date, the company has reported that dosages for cohorts one, two and three were well tolerated and no serious adverse events have been observed
- The trial is being funded by Australia’s largest independent funder of MND research, FightMND who have committed $881,085 to the cause
- Shares rose 10.1 per cent to 7.6 cents at 1:47 pm AEST
PharmAust (PAA) has announced that all 12 patients in cohort three have received an initial escalated dose in its phase one/two trial of monepantel (MPL) in Motor Neurone Disease (MND) and Amyotrophic Lateral Sclerosis (ALS).
The trial had patients with MND and ALS enrolled at two sites in Victoria and New South Wales.
Patients were split into four cohorts each with escalating MPL doses.
The trials are designed to test the tolerability, safety, pharmacokinetics and preliminary efficacy of the drug in people living with MND.
To date, the company has reported that dosages for cohorts one, two and three were well tolerated and no serious adverse events have been observed.
Results from the trial are being analysed by three separate Australian institutions to explore how the drug impacts signalling pathways to slow the progress of the disease in patients with MND.
MND is a progressive disease, with no cure which leads to the degeneration of motor neurones in the brainstem, impacting all functions within the body, eventually leading to death.
The phase one/two trial is being funded by Australia’s largest independent funder of MND research, FightMND who have committed $881,085 to the cause.
If the trials are successful, PharmAust is hoping to receive orphan drug designation by the Therapeutic Goods Association and Food and Drug Administration for MND.
PharmAust rose 10.1 per cent to 7.6 cents at 1:47 pm AEST.